Request Demo

Last update 04 Apr 2026

Dexamethasone Sodium Phosphate

Last update 04 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dex 21-P, Dexamethasone 21-Phosphate, eDSP

+ [23]

Target

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [10]

Active Indication

Brain EdemaCOVID-19Respiratory Distress Syndrome, Acute+ [38]

Inactive Indication

AnaphylaxisCataractDry Eye Syndromes+ [16]

Originator Organization

Merck & Co., Inc.

Active Organization

AVM Biotechnology LLC

Hameln pharma Gmbh.Wockhardt UK Ltd.

+ [8]

Inactive Organization

Kiora Pharmaceuticals, Inc.

Aspen Global, Inc.Semnur, Inc.

+ [5]

License Organization

Taiwan Liposome Co., Ltd.

Bausch Health Cos., Inc.

Endo International Plc

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (26 Aug 1959)

RegulationOrphan Drug (United States), Orphan Drug (European Union), Fast Track (United States)

Structure/Sequence

Molecular FormulaC22H30FNaO8P

InChIKeyVIKBYTWZYXGHAT-WKSAPEMMSA-N

CAS Registry2392-39-4

2,746

Clinical Trials associated with Dexamethasone Sodium Phosphate

NCT04366115

/ Not yet recruitingPhase 1

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

Start Date01 Dec 2026

Sponsor / Collaborator

AVM Biotechnology LLC

[+1]

NCT07444710

/ Not yet recruitingPhase 1IIT

A Phase I Study of Glofitamab With Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma

This phase I trial tests the safety, side effects and best dose of glofitamab given with alternating cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)/ rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) for the treatment of mantle cell lymphoma. Glofitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone and dexamethasone are in a class of medications called corticosteroids. They are used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Chemotherapy drugs, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Giving glofitamab may be safe, tolerable and/or effective in treating patients with mantle cell lymphoma.

Start Date20 Aug 2026

Sponsor / Collaborator

National Cancer Institute

NCT07498998

/ Not yet recruitingNot ApplicableIIT

A Comparative Study Between Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome

This study aims to compare the efficacy and outcomes of perineural injection with 5% dextrose, local ozone and glucocorticoid injection in the management of carpal tunnel syndrome.

Start Date30 Jul 2026

Sponsor / Collaborator

Tanta University

100 Clinical Results associated with Dexamethasone Sodium Phosphate

100 Translational Medicine associated with Dexamethasone Sodium Phosphate

100 Patents (Medical) associated with Dexamethasone Sodium Phosphate

1,521

Literatures (Medical) associated with Dexamethasone Sodium Phosphate

04 Mar 2026·Pain Management

Long-acting dexamethasone viscous gel (SP-102) transforaminal injection for lumbosacral radicular pain

Review

Author: Ferrer Gonzalez, Daniela A ; Knezevic, Nebojsa Nick ; George, Conor

Lumbosacral radicular pain (LRP) is a condition characterized by debilitating pain and functional impairment. Epidural steroid injections (ESIs) are frequently used to relieve symptoms of LRP; there are currently no FDA-approved corticosteroid products specifically indicated for this condition. Moreover, existing products carry safety warnings against epidural administration, which have been linked to the off-label use of formulations. SP-102 (10 mg dexamethasone in a 2 ml viscous gel) is a proposed product that is formulated to provide rapid onset of action while prolonging the duration of effect, potentially resulting in extended pain relief and an improved safety profile for dexamethasone. Phase I and phase II studies have demonstrated SP-102 to be safe and well-tolerated. In phase III, SP-102 demonstrated greater pain relief compared to placebo; SP-102 reduced leg pain scores by an average of 1.1 points more than placebo over four weeks (p < 0.001) and extended the median time before repeat injection to 84 days compared with 58 days for placebo. SP-102 also produced an average 8.9-point reduction in the Oswestry Disability Index (ODI) from baseline versus 5.5 points with placebo (p = 0.015). Importantly, no serious adverse events related to the injection of SP-102 were reported.

02 Mar 2026·JOURNAL OF VETERINARY INTERNAL MEDICINE

A randomized, masked, crossover, clinical trial of the efficacy and safety of nebulized albuterol sulfate and dexamethasone sodium phosphate in asthmatic horses

Article

Author: Marmolejo, Jackeline Franco ; Ivester, Kathleen M ; Mukhopadhyay, Abhijit ; Tyson, Kira N ; Couetil, Laurent L ; Murray, Laura ; Jannasch, Amber

Abstract:

Background:

Nebulization of injectable dexamethasone sodium phosphate (DSP; 0.01 mg/kg) to horses with severe equine asthma (SEA) was previously found to be ineffective. Horses with SEA have marked bronchoconstriction that decreases peripheral lung deposition of nebulized drugs. Administration of a bronchodilator immediately before nebulizing dexamethasone may improve efficacy.

Hypothesis/Objectives:

Evaluate the therapeutic effects and optimal dose of nebulized DSP after nebulized albuterol in horses with SEA.

Animals:

Seven horses with SEA from a research herd.

Methods:

In this masked randomized crossover trial, horses were assigned to one of 3 treatment groups: (1) 0.04 mg/kg DSP IV; (2) 0.01 mg/kg DSP by nebulization; and (3) 0.02 mg/kg DSP by nebulization, in a 3 × 3 Latin square design. All horses were treated q24h for 7 days and received albuterol (0.3 μg/kg) 10 min before DSP. Clinical score, pulmonary function testing, bronchoalveolar lavage fluid (BALF) cytology, adrenocorticotropic hormone stimulation test, plasma and BALF DSP concentrations and routine blood test results were compared between groups and over time.

Results:

Nebulized DSP resulted in similar lung deposition as IV DSP but did not suppress adrenocortical function. However, nebulized DSP did not improve clinical signs, lung function, or BALF cytology. Only IV DSP improved lung function. None of the treatments performed influenced BALF neutrophil proportions.

Conclusions and clinical importance:

Nebulization of albuterol before DSP minimizes systemic absorption of dexamethasone and preserves adrenal function of horses with SEA. Our results do not support the use of nebulized DSP at the doses used for the treatment of SEA.

24 Feb 2026·AMERICAN JOURNAL OF VETERINARY RESEARCH

Repeated intravenous dexamethasone administration causes transient changes in leukocyte parameters in healthy warmblood horses

Article

Author: Vendrig, Johannes C. ; Hendrikx, Anne L. ; Roelfsema, Ellen ; Gehring, Ronette ; van Alphen, Jennifer ; van den Boom, Robin ; Teske, Erik ; Vernooij, Johannes C. M.

Abstract:

Objective:

To determine the effect of repeated IV administration of dexamethasone (0.06 mg/kg, q 24 h, twice) on WBC parameters in healthy adult horses.

Methods:

This prospective, longitudinal study was conducted from October 7 through November 5, 2024. Five warmblood mares received an IV dexamethasone sodium phosphate injection (DMI) at 0 and 24 hours and an IV injection with 0.9% sodium chloride solution at 48 and 72 hours. Blood samples were collected at 0, 6, 12, 24, 30, 36, 48, 72, 96, and 168 hours, and WBC parameters were evaluated using linear mixed-effects models.

Results:

Leukocyte count, neutrophil count, and neutrophil-to-lymphocyte ratio were increased at 6 hours after DMI. Mean leukocyte count peaked 6 hours after DMI and exceeded the reference interval; however, not all horses had peaks above the reference interval. Neutrophilia was observed in all horses, with peak values 6 hours after DMI. Lymphocyte, monocyte, and eosinophil counts were decreased at 6 hours after DMI, with complete suppression of eosinophils. Myeloperoxidase index was increased only at 6 hours after the second DMI. Neut-X was decreased at 12 hours after DMI, and Neut-Y did not change up to 156 hours after the first DMI. Most parameters returned to baseline at 48 to 72 hours.

Conclusions:

Repeated IV dexamethasone administration induces recognizable changes in leukograms in healthy horses with transient neutrophilia combined with increased leukocyte counts and neutrophil-to-lymphocyte ratios and decreased lymphocyte, monocyte, and eosinophil counts.

Clinical Relevance:

Recognition of glucocorticoid-induced changes is important for accurate interpretation of hematologic findings in horses receiving glucocorticoids.

308

News (Medical) associated with Dexamethasone Sodium Phosphate

31 Mar 2026

·www.biospace.com

CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

– Enrollment underway in UK and U.S. for initial registration-supporting study; first patient dosed at The Royal Marsden NHS Foundation Trust in London – – InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or anti-BCMA therapy – CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating inobrodib 20 mg in combination with standard doses of pomalidomide (pom) and dexamethasone (dex; InoPd) in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM). The first patient was dosed at The Royal Marsden NHS Foundation Trust in London. Additional sites are now open in the UK and U.S. “Dosing the first patient in DOMMINO-1 marks an important milestone as we advance InoPd in registration-enabling studies,” said Naseer Qayum M.D., Ph.D., Chief Strategy Officer and Head of R&D at CellCentric. “Inobrodib 20 mg with pom + dex has demonstrated encouraging clinical activity, including a 60% objective response rate, and a tolerability pro with pom-dex alone. Patients who are refractory to pomalidomide and have progressed following bispecifics or other BCMA-directed therapies have very limited options. We believe InoPd may deliver a transformative all-oral treatment for RRMM patients and look forward to further evaluating its potential in this Phase 2 trial.” Care for patients with multiple myeloma has transformed over the last two decades. It is a condition treated with serial therapeutic options. Inobrodib represents a new modality complementary to existing treatments and potentially addresses a major unmet need. “Advances in multiple myeloma treatment, including bispecific antibodies, have improved patient outcomes. However, many people ultimately relapse or become refractory to these therapies, and new treatment options are urgently needed,” said Charlotte Pawlyn, M.D., Honorary Consultant Hematologist at The Royal Marsden NHS Foundation Trust, Group Leader in Myeloma Biology and Therapeutics at The Institute of Cancer Research, London, and Principal Investigator for the DOMMINO‑1 study. “Inobrodib represents a novel mechanism through inhibition of p300/CBP and has demonstrated the ability to be used in combination with established therapies. We look forward to further evaluating InoPd in this trial.” DOMMINO-1 is a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S. (NCT07096778) . The trial is designed to assess the safety and efficacy of InoPd, with participants receiving inobrodib at a 20 mg dose, as supported by recent dose-optimization work (Project Optimus), shared with the U.S. Food and Drug Administration (FDA) and other regulatory agencies. The primary endpoint is overall response rate, with secondary endpoints including progression-free survival, overall survival and duration of response. Eligible participants in this study, specifically, must have previously received a bispecific antibody and be refractory to at least one proteasome inhibitor, one anti-CD38 monoclonal antibody and pomalidomide. “InoPd appears to be a promising option in multiple myeloma treatment, not only for its tolerability and efficacy observed to date, but also for the practical benefits it may offer patients,” said Nisha Joseph, M.D., Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine in Atlanta and DOMMINO-1 principal investigator at the first U.S. trial site. “More than 70% of patients are treated in the community setting, and an all-oral regimen may facilitate and expand access for those living with this disease, as well as their caregivers and healthcare providers.” About Inobrodib Inobrodib is a potential new treatment for people with multiple myeloma and other cancers. It has been evaluated in over 450 patients to date. Clinical activity has been seen in both hematologic malignancies and solid tumors. Delivered as an oral capsule, inobrodib is easy for patients to take and designed to be used at home without the need for intensive monitoring. Alongside InoPd, inobrodib is also being explored in combination with bispecific therapies elranatamab and teclistamab. Proof of concept in a maintenance setting is also being explored. CellCentric maintains all development and commercial rights to inobrodib and is free to expand the program in combination with other agents. The U.S. FDA previously granted Fast Track and Orphan Drug Designations to inobrodib for RRMM. About CellCentric CellCentric is a privately held biotechnology company focused on advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. The company is transatlantic, with offices in the UK and U.S. The company is backed by a global syndicate of life science investors, including RA Capital Management, Forbion (and ForCal), Morningside, Pfizer Ventures, Avego and the American Cancer Society’s BrightEdge Fund. References Joseph N. Randomized Phase II Dose-Optimization Study of Inobrodib in Combination with Pom+Dex in Relapsed/Refractory Multiple Myeloma. American Society of Hematology Congress, 2025, Orlando, USA. Weisel K., et al. Real-life outcomes in patients with BCMA-exposed relapsed/refractory multiple myeloma treated with standard of care in the LocoMMotion and MoMMent studies. European Hematology Association Congress, 2024; Madrid, Spain. Contacts Investor Contact: info@cellcentric.com Media Contact: ashlea@1abmedia.com

Phase 2Orphan DrugFast TrackASHClinical Result

30 Mar 2026

·www.sciencedaily.com

This overlooked hormone could be why your blood pressure won’t drop

A large U.S. study reveals that more than a quarter of people with hard-to-treat high blood pressure may have an overlooked hormone problem. Elevated cortisol—often linked to stress—was found in 27% of these patients, far higher than expected. This hidden condition could explain why standard medications fail. The discovery could lead to new testing and treatments that finally help bring blood pressure under control.The MOMENTUM study revealed that 27 percent of patients with resistant hypertension have hypercortisolism. This finding is important because it shows that excess cortisol is far more common in these patients than researchers and clinicians previously believed. Resistant hypertension occurs when blood pressure remains high even after taking three or more medications. Nearly 10 million people in the United States are affected by this condition. Researchers are increasingly recognizing that underlying health issues may be preventing standard treatments from working. One of those issues is hypercortisolism, a condition in which the body produces too much cortisol. Often called the "stress hormone," cortisol helps regulate the body's response to stress. However, when cortisol levels stay elevated over time, it can lead to serious health problems. Why This Discovery Matters for Heart Health Patients with resistant hypertension face a higher risk of serious cardiovascular events such as heart attacks and heart failure. At the same time, hypercortisolism is linked to complications including weight gain, muscle loss, and diabetes. Identifying excess cortisol as a contributing factor may help explain why some patients struggle to control their blood pressure. It also opens the possibility that treating hypercortisolism could provide a new way to lower blood pressure when standard therapies are not effective. Largest U.S. Study of Its Kind "MOMENTUM" is the first study conducted in the United States and the largest to date to measure how common hypercortisolism is among patients with resistant hypertension. Researchers evaluated 1,086 participants across 50 centers nationwide, including Mount Sinai Health System in New York. After confirming eligibility, participants underwent a dexamethasone suppression test. This involved taking a dose of dexamethasone at night and having blood drawn the next morning to measure cortisol levels. Patients with cortisol levels above 1.8 ug/dL were classified as having hypercortisolism. Study Results and Additional Risk Factors Out of 1,086 participants, 297 were found to have hypercortisolism, representing 27 percent of the group. The study also identified factors that increase the likelihood of having this condition. For instance, patients with reduced kidney function were more likely to have elevated cortisol levels. Another condition linked to resistant hypertension is "primary hyperaldosteronism," which occurs when the body produces too much aldosterone. About 20 percent of participants had this disorder, and roughly 6 percent had both hypercortisolism and hyperaldosteronism. What Patients and Doctors Should Do Next The findings suggest that physicians should consider elevated cortisol as a possible cause of resistant hypertension and screen patients who are at higher risk. Testing is relatively simple, and many patients are eager to find an explanation for why their blood pressure remains difficult to control. Patients whose blood pressure stays high despite multiple medications may benefit from asking their doctor about screening for hypercortisolism. Expert Perspective "The fact that such a high percentage (more than 25 percent) of patients with resistant hypertension have elevated cortisol levels is very different from what doctors have been historically taught in medical school. These findings should prompt more screening for excess levels of cortisol in patients with resistant hypertension," says Deepak L. Bhatt, MD, MPH, MBA. "The next step to further this research is conducting randomized trials to determine if therapies that lower the impact of cortisol can safely and effectively treat high blood pressure in these patients." Study Funding and Presentation Study Funding: Corcept Therapeutics Incorporated was the study sponsor and funded the study. Dr. Bhatt is a paid consultant for Corcept Therapeutics Incorporated. Meeting: American College of Cardiology's Annual Scientific Session

Clinical ResultAHA

25 Mar 2026

·www.biospace.com

Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road

iStock, beast01 Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts. Karyopharm Therapeutics’ push to expand its multiple myeloma drug Xpovio into myelofibrosis has hit a speedbump. Tuesday, the biotech unveiled mixed results in a Phase 3 myelofibrosis study, with an investigational Xpovio regimen meeting just one of two primary endpoints. Following the readout, the company’s shares dropped to $5.44 apiece at market close, an 18.3% decrease from its previous closing price. Karyopharm nevertheless intends to engage with the FDA to discuss “the totality of the data” and see how that might shape up to a regulatory path forward for Xpovio in this indication, according to a Tuesday release . Jefferies, however, isn’t optimistic: “We see low chance of conventional FDA approval w/ current dataset,” analysts told investors in a note sent the same day. Xpovio is an oral nuclear export inhibitor that was approved in 2019 in combination with dexamethasone for patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy. Last year, the drug made $114.9 million . Karyopharm forecasts net U.S. product revenue to be between $115 million to $130 million this year. In the Phase 3 SENTRY study , Karyopharm combined Xpovio with ruxolitinib, a JAK inhibitor that is marketed by Incyte under brand names such as Jakafi and Opzelura. The trial enrolled more than 350 patients with myelofibrosis and who had never been treated with JAK inhibitors. Comparators were given placebo plus ruxolitinib. At 24 weeks, 50% of patients treated with the Xpovio combo achieved at least a 35% decrease in spleen volume, a key disease marker. At the same time point, 28% of comparators on ruxolitinib alone hit this endpoint, resulting in a statistically significant advantage for the Xpovio regimen. Xpovio was able to sustain this benefit over time, with 47% of patients maintaining a 35% spleen volume reduction by 36 weeks, versus 23% in controls. However, the Xpovio regimen failed to hit SENTRY’s other co-primary endpoint of symptom improvement, as measured by a change in the absolute total symptom score. Patients treated with Karopharm’s combo saw a 9.89-point improvement in the scale, versus 10.86 points in those who received ruxolitinib alone. A key opinion leader consulted by RBC Capital Markets “did not seem as concerned about the trial not hitting on its symptom scale endpoint,” the firm told investors in a Tuesday note. The expert, RBC continued, pointed out that ruxolitinib’s symptomatic benefits “are so robust that . . . it may not be possible for any drug to hit on this endpoint.” What interested the expert more were the survival signals that Karyopharm reported. The biotech touted “promising” overall survival (OS) outcomes in its Tuesday release, with the Xpovio- ruxolitinib combo reducing the risk of death from any cause by 57% versus controls. A posthoc analysis also showed that the spleen volume response could be predictive of overall survival. While RBC’s key opinion leader has expressed “some caution” about whether this survival signal is real, he nevertheless “believes this would be a very meaningful finding if it plays out longer-term,” the firm said. A significant survival benefit, analysts added, would trump the symptom score miss. Karyopharm intends to present its OS data to the FDA in building its case for Xpovio’s expansion into myelofibrosis, the biotech said on Tuesday, though it did not yet provide a specific timeline for when such a filing could occur.

Clinical ResultPhase 3Drug Approval

100 Deals associated with Dexamethasone Sodium Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D00975	Dexamethasone Sodium Phosphate	D07AB19 H02AB02 D10AA03	DB01234

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Brain Edema	Austria	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Belgium	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Bulgaria	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Croatia	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Czechia	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Denmark	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Finland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Germany	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Hungary	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Iceland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Ireland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Italy	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Netherlands	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Norway	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Poland	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Portugal	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Romania	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Slovakia	Hameln pharma Gmbh.	28 Apr 2021
Brain Edema	Slovenia	Hameln pharma Gmbh.	28 Apr 2021
COVID-19	Austria	Hameln pharma Gmbh.	28 Apr 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 3	United States	TLC BioSciences	26 Nov 2019
Osteoarthritis, Knee	Phase 3	United States	Taiwan Liposome Co., Ltd.	26 Nov 2019
Osteoarthritis, Knee	Phase 3	Australia	Taiwan Liposome Co., Ltd.	26 Nov 2019
Osteoarthritis, Knee	Phase 3	Australia	TLC BioSciences	26 Nov 2019
Radicular Pain	Phase 3	United States	Scilex Pharmaceuticals, Inc.	08 Dec 2017
Radiculopathy	Phase 3	United States	Scilex Pharmaceuticals, Inc.	08 Dec 2017
Ataxia Telangiectasia	Phase 3	United States	Quince Therapeutics, Inc.	02 Mar 2017
Ataxia Telangiectasia	Phase 3	Australia	Quince Therapeutics, Inc.	02 Mar 2017
Ataxia Telangiectasia	Phase 3	Belgium	Quince Therapeutics, Inc.	02 Mar 2017
Ataxia Telangiectasia	Phase 3	Germany	Quince Therapeutics, Inc.	02 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Thalassemia	19	Fludarabine 120 mg/m2 + Dexamethasone 80 mg/m2 + Flu + Bu + Cy + ATG	dqvkqdbcvb(gnacusyuok) = ujieauvrud lwpwfaolgi (nkarejfhhm ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Non-Hodgkin Lymphoma	59	Axi-cel + dex prophylaxis	mnriyfrumc(szfluxtyfk) = qczfzpqpwd axczwfbpty (prlmlegmfg ) View more	Positive	04 Feb 2026
				Liso-cel	mnriyfrumc(szfluxtyfk) = ooaviqgzry axczwfbpty (prlmlegmfg ) View more
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Multiple Myeloma	71	Daratumumab+Bortezomib+Lenalidomide+Dexamethasone	vrfwdeigdx(kdpzifkbic) = uzqvxuhmya vdjxjqdjtz (moqytgjtxi ) View more	Positive	04 Feb 2026
				Daratumumab+Bortezomib+Lenalidomide+Dexamethasone (2025 IMS/IMWG high-risk criteria)	vrfwdeigdx(kdpzifkbic) = zvwxxyhhfa vdjxjqdjtz (moqytgjtxi ) View more
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Multiple Myeloma	140	Daratumumab+ bortezomib/cafilzomib+ lenalidomide+ dexamethasone (CD34+ cells <5×10^6/kg)	puljdwcyea(keewjlnkzy) = bhojrannwk jmpbowolxs (ezujkllzbq ) View more	Positive	04 Feb 2026
				Daratumumab+ bortezomib/cafilzomib+ lenalidomide+ dexamethasone (CD34+ cells ≥5×10^6/kg)	puljdwcyea(keewjlnkzy) = nasnsdhkyl jmpbowolxs (ezujkllzbq ) View more
NCT06193200 (NEAT \| IEDAT-04-2022, Company_Website) Manual	Phase 3	Ataxia Telangiectasia	105	eDSP	frhviuwqhw(qhbqwsakxi) = xibqhclbwp xnoiprenjr (hhswubrjkc )	Negative	29 Jan 2026
				placebo	frhviuwqhw(qhbqwsakxi) = anycdwzjyh xnoiprenjr (hhswubrjkc )
NCT02389517 (CTgov)	Phase 2	Multiple Myeloma \| Residual Neoplasm	42	Lenalidomide+Ixazomib Citrate+Dexamethasone (Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone))	vjzrobhkmu = vcrvzomprs sdcznlvpyc (uapjvnpsgx, gmlfiblxuk - qskwajftti) View more	-	22 Jan 2026
				Lenalidomide (Arm II (Lenalidomide))	vjzrobhkmu = pteecnyvsn sdcznlvpyc (uapjvnpsgx, bkgsnvmtme - zqvmcyvxjp) View more
NCT06006624 (Pubmed \| Orthop J Sports Med)	Phase 4	-	131	Liposomal bupivacaine	bxqlebjxfe(kpnmblptbo) = pavfylirqo hqnpxqhuox (okyyitvyei, 21.9)	Positive	01 Jan 2026
				Liposomal bupivacaine + dexamethasone	bxqlebjxfe(kpnmblptbo) = znrdzyasfi hqnpxqhuox (okyyitvyei, 14.33)
NCT03389620 (CTgov)	Phase 2	Radiculopathy	74	dexamethasone (Transforaminal Cervical Epidural Corticosteroid Injections)	jukyubywre(bjksspeumk) = mifpmlrxpf ycqmqfbtvc (hmtfpulyob, 2.50) View more	-	19 Dec 2025
				dexamethasone (Lateralized Interlaminar Epidural Corticosteroid Injections)	jukyubywre(bjksspeumk) = tudrimccqw ycqmqfbtvc (hmtfpulyob, 2.20) View more
ASH2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic First line	226	Dexamethasone 40 mg daily for 4 days with additional courses as needed	kuixcnpywv(tstfajsjrn) = iarseomdls ashwaimpcd (gzhagkcrrz, 27.3 - 47.9) View more	Negative	06 Dec 2025
				Prednisone with tapering down	kuixcnpywv(tstfajsjrn) = mmuqzthygj ashwaimpcd (gzhagkcrrz, 6.8 - 18.7) View more
ASH2025	Not Applicable	Multiple Myeloma First line	1,721	CD38 Antibody, Immunomodulator, Proteasome Inhibitor, and Dexamethasone	qvszitltzk(xhuokugrnj) = orsvdpmmov tgbmcqaevf (riqfcsbyvf ) View more	Negative	06 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis